美国联合医疗(UTHR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

UTHR 美国联合医疗

交易中 09-14 11:23:34 EDT

505.27

+8.16

+1.64%

最高509.07	最低499.62	成交量10.44万
今开506.68	昨收497.11	日振幅1.90%
总市值216.71亿	流通市值198.82亿	总股本4,289万
成交额5,273万	换手率0.27%	流通股本3,935万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"UTHR","market":"US","secType":"STK","nameCN":"美国联合医疗","latestPrice":505.27,"timestamp":1789399409701,"preClose":497.11,"halted":0,"volume":104373,"delay":0,"changeRate":0.016414877994809937,"floatShares":39350000,"shares":42890700,"eps":27.94838,"marketStatus":"交易中","change":8.16,"latestTime":"09-14 11:23:34 EDT","open":506.68,"high":509.065,"low":499.62,"amount":52730377.2657,"amplitude":0.019,"askPrice":505.26,"askSize":45,"bidPrice":504.67,"bidSize":12,"shortable":3,"etf":0,"ttmEps":27.94838,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1789416000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":929592000000,"exchange":"NASDAQ","adjPreClose":497.11,"preHourTrading":{"tag":"盘前","latestPrice":507.22,"preClose":497.11,"latestTime":"09:29 EDT","volume":260,"amount":131489.0798,"timestamp":1789392599999,"change":10.11,"changeRate":0.020338,"amplitude":0.022847},"postHourTrading":{"tag":"盘后","latestPrice":497.11,"preClose":497.11,"latestTime":"19:30 EDT","volume":216756,"amount":107752147.21,"timestamp":1789169405932,"change":0,"changeRate":0,"amplitude":0.005814},"volumeRatio":0.661921,"impliedVol":0.3186,"impliedVolPercentile":0.1235},"requestUrl":"/m/hq/s/UTHR","defaultTab":"news","newsList":[{"id":"1191906934","title":"美国联合医疗将依据2026年9月8日股价，率先接收75%的已回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1191906934","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191906934?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:02","pubTimestamp":1788865376,"startTime":"0","endTime":"0","summary":"美国联合医疗公司（United Therapeutics）宣布，将依据2026年9月8日的股价，接收首批交付的回购股份，这批股份占比达回购总量的75%。这一举措标志着公司回购计划进入实质性执行阶段。市场方面，此次交付安排或对短期股价波动产生一定影响。分析人士指出，回购进度的分批推进，有助于平滑市场冲击，同时体现管理层对资本结构的审慎优化意图。随着首批股份到账，公司后续回购节奏与资金运用效率，将成为投资者关注的新焦点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","LU1699723380.USD","UTHR","BK4139","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664814414","title":"联合治疗（UTHR）雾化吸入剂Tyvaso扩大适应症申请获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664814414","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664814414?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:52","pubTimestamp":1788353572,"startTime":"0","endTime":"0","summary":"金吾财讯 | 联合治疗（UTHR）宣布，美国食品药品监督管理局（FDA）已正式受理其核心产品Tyvaso（曲前列尼尔，Treprostinil）雾化吸入剂的补充新药申请，用以扩大其在美国的标签范围，拓展至特发性肺纤维化（IPF）的治疗。据官方披露，FDA预计将于2027年4月下旬完成对该项申请的审查。若该申请顺利获批，雾化Tyvaso将成为全美首个且唯一用于治疗特发性肺纤维化的吸入式抗纤维化药物，极大改善患者给药体验与疗效。","market":"other","thumbnail":"https://static.szfiu.com/news/20210625/YjE5NjM0NjA5NTUxNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YjE5NjM0NjA5NTUxNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305638","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LABU","LU1571399168.USD","LU1699723380.USD","UTHR","BK4532","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143550350","title":"美国联合医疗宣布：FDA受理Ralinepag治疗肺动脉高压新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1143550350","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143550350?lang=zh_cn&edition=full","pubTime":"2026-08-24 19:07","pubTimestamp":1787569638,"startTime":"0","endTime":"0","summary":"美国联合医疗（United Therapeutics）近日宣布，美国食品药品监督管理局（FDA）已正式受理其针对Ralinepag的新药申请，该药物旨在治疗肺动脉高压这一严重疾病。此项进展标志着该公司在心血管疾病治疗领域的又一重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4532","LU1699723380.USD","UTHR","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177842660","title":"美国联合医疗：Ralinepag尚未获得FDA批准，仍处于肺动脉高压研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1177842660","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177842660?lang=zh_cn&edition=full","pubTime":"2026-08-24 19:01","pubTimestamp":1787569268,"startTime":"0","endTime":"0","summary":"美国联合医疗公司今日发布重要声明：其研发的药物Ralinepag，目前尚未获得美国食品药品监督管理局（FDA）对任何适应症的批准，该药物仍处于肺动脉高压（PAH）的研究性阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1699723380.USD","LU1571399168.USD","UTHR","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196098833","title":"美国联合医疗宣布Teton-PPF研究完成入组：吸入性曲前列尼尔治疗进行性肺纤维化","url":"https://stock-news.laohu8.com/highlight/detail?id=1196098833","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196098833?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:01","pubTimestamp":1786964487,"startTime":"0","endTime":"0","summary":"美国联合医疗今日正式宣布，其针对吸入性曲前列尼尔治疗进行性肺纤维化的Teton-PPF研究已圆满完成全部患者入组。据悉，Teton-PPF研究是一项关键性临床试验，旨在评估吸入性曲前列尼尔在延缓进行性肺纤维化疾病进展方面的疗效与安全性。美国联合医疗表示，将继续致力于推进该项目的开发，以期早日为患者带来突破性疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4532","UTHR","LU1699723380.USD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167235408","title":"财报前瞻｜美国联合医疗本季度营收预计小幅增长，机构偏向审慎乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1167235408","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167235408?lang=zh_cn&edition=full","pubTime":"2026-07-30 00:09","pubTimestamp":1785341342,"startTime":"0","endTime":"0","summary":"美国联合医疗将在2026年08月05日发布最新季度财报，市场关注营收恢复与利润率稳定性以及核心吸入/雾化产品放量节奏。市场一致预期显示，本季度美国联合医疗营收预计为8.06亿美元，同比增长0.17%；EBIT预计为3.89亿美元，同比增长5.39%；预计调整后每股收益为6.83美元，同比下降1.56%。一线机构普遍认为，本季度收入有望回到小幅正增长轨道，EBIT率在费用投放平衡后趋于稳定，EPS虽受阶段性投入拖累但具备中期修复条件。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜美国联合医疗本季度营收预计小幅增长，机构偏向审慎乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169631569","title":"美国联合医疗：Ralinepag治疗肺动脉高压III期临床研究达到主要及次要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1169631569","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169631569?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:34","pubTimestamp":1785321261,"startTime":"0","endTime":"0","summary":"美国联合医疗（United Therapeutics）宣布，其用于治疗肺动脉高压（PAH）的药物Ralinepag，在名为Advance Outcomes的III期临床研究中，成功达到了预设的主要终点与次要终点。这一突破性进展，为肺动脉高压患者带来了新的治疗希望。该研究结果不仅验证了药物的核心疗效，更在多个关键评估指标上展现出显著性优势，标志着Ralinepag在攻克这一罕见且凶险的疾病上迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UTHR","BK4139","LU1699723380.USD","BK4532","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114839620","title":"美国联合医疗宣布Lungfx™设备获FDA批准用于集中式离体肺灌注","url":"https://stock-news.laohu8.com/highlight/detail?id=1114839620","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114839620?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:38","pubTimestamp":1782729494,"startTime":"0","endTime":"0","summary":"美国联合医疗公司宣布，其Lungfx™设备已获得美国食品药品监督管理局的批准，可用于集中式的离体肺灌注操作。这一监管里程碑标志着公司在器官护理技术领域取得了重要进展，有望提升供体肺的评估、修复和利用效率，从而为更多等待肺移植的患者带来希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1699723380.USD","UTHR","LU1571399168.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185929543","title":"Varda Space Industries与联合医疗携手推进微重力罕见肺病疗法研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1185929543","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185929543?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:02","pubTimestamp":1778666549,"startTime":"0","endTime":"0","summary":"Varda Space Industries与联合医疗（United Therapeutics）达成合作，共同致力于利用微重力环境开发针对罕见肺部疾病的创新疗法。此次合作旨在探索太空环境对药物研发与生产可能带来的革命性影响，为相关治疗领域开辟新的技术路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UTHR","BK4532","BK4139","LU1571399168.USD","LU1699723380.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106467182","title":"美国联合医疗董事雷蒙德·德韦克教授荣休 曾获C.B.E.及F.R.S.殊荣","url":"https://stock-news.laohu8.com/highlight/detail?id=1106467182","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106467182?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:08","pubTimestamp":1777460917,"startTime":"0","endTime":"0","summary":"美国联合医疗公司（United Therapeutics Corporation）近日宣布，公司董事会成员雷蒙德·德韦克教授（Professor Raymond Dwek, C.B.E., F.R.S.）正式退休。德韦克教授在任期间以其深厚的学术造诣和卓越贡献备受赞誉，其荣休标志着公司治理层一个重要时代的落幕。\n作为曾获授大英帝国司令勋章（C.B.E.）及英国皇家学会院士（F.R.S.）的杰出科学家，德韦克教授在生物医学领域的专业见解为董事会决策提供了重要支撑。他的离任虽令人不舍，但公司对其多年来的服务表示深切感谢，并祝愿他在未来的学术与生活中再创辉煌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1699723380.USD","BK4532","LU1571399168.USD","UTHR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180302098","title":"美国联合医疗：Raymond James首予跑赢大市评级，目标价700美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180302098","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180302098?lang=zh_cn&edition=full","pubTime":"2026-04-10 19:24","pubTimestamp":1775820297,"startTime":"0","endTime":"0","summary":"美国联合医疗（United Therapeutics）近日获得Raymond James的首次覆盖，该机构给予其\"跑赢大市\"评级，并将目标股价设定为700美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","BK4139","BK4532","UTHR","LU1699723380.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159418166","title":"美国联合医疗Miroliverelap®获FDA再生医学先进疗法认定，用于急性肝衰竭治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1159418166","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159418166?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:03","pubTimestamp":1775646225,"startTime":"0","endTime":"0","summary":"美国联合医疗（United Therapeutics）宣布，其研发的药物Miroliverelap®已获得美国食品药品监督管理局（FDA）授予的再生医学先进疗法（RMAT）认定，适应症为急性肝衰竭。这一认定将加速该疗法的开发和审评进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4532","UTHR","LU1699723380.USD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161460841","title":"美国联合医疗股价飙升14.71%：吸入式药物Tyvaso在晚期特发性肺纤维化研究中达成主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1161460841","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161460841?lang=zh_cn&edition=full","pubTime":"2026-03-30 21:32","pubTimestamp":1774877577,"startTime":"0","endTime":"0","summary":"美国联合医疗（United Therapeutics）宣布，其吸入式药物Tyvaso在一项针对特发性肺纤维化的晚期临床研究中成功达成主要试验目标。受此利好消息提振，该公司股价大幅跃升14.71%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","LU1699723380.USD","UTHR","BK4139","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109130837","title":"美国联合医疗计划为Tyvaso申请优先审评 补充新药申请将于今夏末提交FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=1109130837","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109130837?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:10","pubTimestamp":1774869014,"startTime":"0","endTime":"0","summary":"美国联合医疗公司宣布，将为旗下药物Tyvaso的补充新药申请（sNDA）寻求优先审评资格。该公司计划于今年夏季结束前向美国食品药品监督管理局（FDA）正式提交该项申请。\n优先审评资格将加速FDA对Tyvaso申请的审批流程，若获批准，有望使该药物更早惠及患者。此次申报标志着公司在拓展Tyvaso适应症方面迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1699723380.USD","BK4532","LU1571399168.USD","UTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166965135","title":"美国联合医疗宣布Tyvaso®治疗特发性肺纤维化Teton-1关键研究达主要终点，疗效超越Teton-2显著成果","url":"https://stock-news.laohu8.com/highlight/detail?id=1166965135","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166965135?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:03","pubTimestamp":1774868588,"startTime":"0","endTime":"0","summary":"美国联合医疗公司公布，其研发的Tyvaso®在治疗特发性肺纤维化的Teton-1关键性研究中成功达到主要临床终点。该研究展现的治疗效果甚至超越了此前Teton-2研究中已令人瞩目的数据，标志着其在IPF治疗领域取得重大突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UTHR","LU1571399168.USD","LU1699723380.USD","BK4532","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516854800","title":"美国联合医疗2024财年实现净利润11.95亿美元，同比增加21.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516854800","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516854800?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:00","pubTimestamp":1740931230,"startTime":"0","endTime":"0","summary":"3月3日，美国联合医疗公布财报，公告显示公司2024财年净利润为11.95亿美元，同比增加21.32%；其中营业收入为28.77亿美元，同比增加23.58%，每股基本收益为26.44美元。从资产负债表来看，美国联合医疗总负债9.94亿美元，其中短期债务3.00亿美元，资产负债比为7.49，流动比率为5.25。机构评级：截至2025年3月3日，当前有10家机构对美国联合医疗目标价做出预测，其中目标均价为407.90美元，其中最低目标价为293.00美元，最高目标价为600.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000045abe4ac8b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000045abe4ac8b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["UTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158292312","title":"异动解读 | 财报利润不佳 美国联合医疗公司股价盘中大跌6.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1158292312","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158292312?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:37","pubTimestamp":1740580660,"startTime":"0","endTime":"0","summary":"美国联合医疗今日盘中股价暴跌6.85%,引发市场广泛关注。导致股价大跌的主因是该公司公布的2024年第四季度财报利润不佳。数据显示,联合治疗公司当季每股收益为6.19美元,远低于分析师预期的6.27美元。这一业绩低于预期引发了投资者的担忧,导致其股价在报告当天大幅下挫。综合来看,财报利润不佳造成了投资者对该公司前景的担忧,从而引发了股价在盘中大幅度下跌的走势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["UTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514856083","title":"美国联合医疗盘中异动 股价大跌5.30%报338.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514856083","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514856083?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:31","pubTimestamp":1740580282,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时31分，美国联合医疗股票出现波动，股价快速下跌5.30%。截至发稿，该股报338.54美元/股，成交量1.2718万股，换手率0.03%，振幅0.36%。美国联合医疗股票所在的生物技术行业中，整体涨幅为0.12%。肺动脉高压是一种罕见的进行性疾病，其特征为肺动脉血压异常升高。该公司的所有销售额都在美国境内产生。该公司还销售一种儿科肿瘤药物，但其重点仍然集中于研究肺动脉高压。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223122a254f640&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223122a254f640&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1699723380.USD","BK4139","BK4532","LU1571399168.USD","UTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193208884","title":"联合治疗公司2024年第四季度GAAP每股收益6.19美元，低于预期的6.27美元，销售额为7.359亿美元，高于预期的7.3474亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193208884","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193208884?lang=zh_cn&edition=full","pubTime":"2025-02-26 19:37","pubTimestamp":1740569829,"startTime":"0","endTime":"0","summary":"联合治疗公司报告其季度每股收益为6.19美元，低于分析师预期的6.27美元，差距为1.28%。与去年同期每股收益4.36美元相比，这增加了41.97%。该公司报告其季度销售额为7.359亿美元，高于分析师预期的7.3474亿美元，增长了0.16%。以上内容来自Benzinga Earnings专栏，原文如下：United $Therapeutics$  reported quarterly earnings of $6.19 per share which missed the analyst consensus estimate of $6.27 by 1.28 percent. This is a 41.97 percent increase over earnings of $4.36 per share from the same period last year.  The company reported quarterly sales of $735.90 million which beat the analyst consensus estimate of $734.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"联合治疗公司2024年第四季度GAAP每股收益6.19美元，低于预期的6.27美元，销售额为7.359亿美元，高于预期的7.3474亿美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510336824","title":"美国联合医疗盘中异动 早盘快速上涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510336824","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510336824?lang=zh_cn&edition=full","pubTime":"2025-02-11 23:39","pubTimestamp":1739288398,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日23时39分，美国联合医疗股票出现波动，股价快速上涨5.01%。美国联合医疗股票所在的生物技术行业中，整体跌幅为1.81%。美国联合医疗公司简介：United Therapeutics Corp 是一家专门从事肺动脉高压的药物研发的公司。肺动脉高压是一种罕见的进行性疾病，其特征为肺动脉血压异常升高。该公司的所有销售额都在美国境内产生。该公司还销售一种儿科肿瘤药物，但其重点仍然集中于研究肺动脉高压。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211233959abcb1555&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211233959abcb1555&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU1699723380.USD","LU1571399168.USD","BK4532","UTHR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.unither.com","stockEarnings":[{"period":"1week","weight":0.0195},{"period":"1month","weight":-0.0286},{"period":"3month","weight":-0.0895},{"period":"6month","weight":-0.0728},{"period":"1year","weight":0.2279},{"period":"ytd","weight":0.0202}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"United Therapeutics Corporation于1996年6月成立于特拉华。它是一家生物科技公司，致力于能解决患有慢性病和有生命危险病人未被满足的医疗需求的独特产品的开发和商业化。它的收入主要来源于曲前列尼尔、Tyvaso和他达拉非的销售。他们的市场和销售人员会努力使他们的产品在他们那些被授权的国家买到。这些主要是由他们在美国的专业经销商和其它的国际经销商做的。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.005391},{"month":2,"riseRate":0.518519,"avgChangeRate":0.021742},{"month":3,"riseRate":0.481481,"avgChangeRate":0.013636},{"month":4,"riseRate":0.407407,"avgChangeRate":-0.022031},{"month":5,"riseRate":0.555556,"avgChangeRate":0.047064},{"month":6,"riseRate":0.518519,"avgChangeRate":0.026827},{"month":7,"riseRate":0.571429,"avgChangeRate":0.040787},{"month":8,"riseRate":0.5,"avgChangeRate":0.049715},{"month":9,"riseRate":0.428571,"avgChangeRate":0.052407},{"month":10,"riseRate":0.62963,"avgChangeRate":-0.003162},{"month":11,"riseRate":0.62963,"avgChangeRate":0.05551},{"month":12,"riseRate":0.592593,"avgChangeRate":0.029941}],"exchange":"NASDAQ","name":"美国联合医疗","nameEN":"United Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"美国联合医疗(UTHR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供美国联合医疗(UTHR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"美国联合医疗,UTHR,美国联合医疗股票,美国联合医疗股票老虎,美国联合医疗股票老虎国际,美国联合医疗行情,美国联合医疗股票行情,美国联合医疗股价,美国联合医疗股市,美国联合医疗股票价格,美国联合医疗股票交易,美国联合医疗股票购买,美国联合医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"美国联合医疗(UTHR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供美国联合医疗(UTHR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}